Back to search
Leukocyte Adhesion Defect - Type I
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Leukocyte Adhesion Defect - Type I trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Leukocyte Adhesion Defect - Type I trials you may qualify forBackground: \- Gene therapy is being investigated as a possible treatment for individuals with immunodeficiency diseases or other conditions that make it diffi…
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Ty…
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation. This may include inheri…
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen pai…
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double…
This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safe…
The most important factor determining mortality and morbidity after coronary artery bypass graft (CABG) surgery is graft patency. The LIMA-LAD anastomosis is th…
The objective of this study is to compare different surgical strategies for management of severely diseased LAD artery during CABG i.e. LIMA on-lay patch vs. sa…